Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Has Consensus Target Price of $16.13

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $15.63.

ATEC has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alphatec in a report on Friday, October 30th. BMO Capital Markets cut shares of Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 price objective for the company. in a research note on Friday, October 30th. TD Cowen decreased their price objective on shares of Alphatec from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, October 30th. Wells Fargo & Company lowered their target price on shares of Alphatec from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, October 30th. Finally, Stephens began coverage on shares of Alphatec in a report on Thursday, July 23rd. They issued an “overweight” rating and a $15.00 target price for the company.

Alphatec Stock Down 5.1%

Shares of ATEC stock opened at $7.00 on Wednesday. Alphatec has a 12 month low of $6.81 and a 12 month high of $23.29. The company has a 50 day simple moving average of $9.88 and a two-hundred day simple moving average of $10.29.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Thursday, October 29th. The medical technology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). The company had revenue of $221.17 million during the quarter, compared to the consensus estimate of $225.16 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same period last year, the business earned $0.03 EPS. On average, research analysts expect that Alphatec will post -0.40 earnings per share for the current fiscal year.

Insider Activity

In other Alphatec news, CEO Patrick Miles acquired 115,000 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was purchased at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the purchase, the chief executive officer directly owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. The trade was a 1.99% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Demski bought 60,000 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The shares were acquired at an average price of $6.81 per share, with a total value of $408,600.00. Following the transaction, the director directly owned 491,635 shares of the company’s stock, valued at $3,348,034.35. This represents a 13.90% increase in their position. The disclosure for this purchase is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.48% of the stock is owned by insiders.

Institutional Investors Weigh In On Alphatec

Several institutional investors and hedge funds have recently modified their holdings of ATEC. Kopp Family Office LLC boosted its position in shares of Alphatec by 0.4% during the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company’s stock worth $3,408,000 after acquiring an additional 1,303 shares during the last quarter. SG Americas Securities LLC lifted its stake in Alphatec by 4.2% in the 1st quarter. SG Americas Securities LLC now owns 67,065 shares of the medical technology company’s stock worth $730,000 after purchasing an additional 2,675 shares in the last quarter. Summit Securities Group LLC purchased a new stake in Alphatec in the 1st quarter worth $29,000. Valeo Financial Advisors LLC lifted its stake in Alphatec by 7.2% in the 2nd quarter. Valeo Financial Advisors LLC now owns 44,363 shares of the medical technology company’s stock worth $384,000 after purchasing an additional 2,967 shares in the last quarter. Finally, Allworth Financial LP boosted its holdings in shares of Alphatec by 82.6% during the 2nd quarter. Allworth Financial LP now owns 6,666 shares of the medical technology company’s stock valued at $58,000 after purchasing an additional 3,015 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.